Australia: Incannex cites poor market conditions for listing in US without raising capital

Incannex Healthcare, the ASX-listed developer of medicinal cannabinoid compounds and psychedelic therapies has shelved plans to raise US$27m from a Nasdaq IPO in favour of listing without raising capital. CEO Joel Latham, in his address to shareholders at the AGM, cited weakened market conditions on the Nasdaq and more specifically the Nasdaq Biotech Index, for…

You must be a HMI Subscriber to view this content.

Subscribe Now »